A comparative study of general and severe mycoplasma pneumoniae pneumonia in children
Shuo Yang1, Sukun Lu2, Yinghui Guo3,4
1Institute of Pediatric Research, Children's Hospital of Hebei, 133 Jianhua South Street, Shijiazhuang, 050031, China.
Insights
Severe Mycoplasma pneumoniae pneumonia (SMPP) in children is linked to increased inflammation and extrapulmonary issues. Effective management may include hormonal therapy, anticoagulation, and non-macrolide antibiotics for co-infections.
Area of Science:
- Pediatrics
- Infectious Diseases
- Respiratory Medicine
Background:
- Severe Mycoplasma pneumoniae pneumonia (SMPP) is an increasing concern in pediatric populations.
- Understanding the characteristics and outcomes of SMPP is crucial for effective treatment strategies.
Purpose of the Study:
- To characterize children with SMPP and assess their clinical outcomes.
- To identify factors associated with severe disease and complications in pediatric MPP.
Main Methods:
- Retrospective analysis of children hospitalized with Mycoplasma pneumoniae pneumonia (MPP) from January to December 2022.
- Data collected included demographics, clinical features, comorbidities, laboratory results, and treatment outcomes.
- Disease severity was classified based on established pediatric community-acquired pneumonia guidelines.
Main Results:
- Over 400 children with MPP were analyzed, with 50.6% diagnosed with SMPP.
- SMPP cases showed higher rates of underlying diseases, extrapulmonary complications (myocardial, digestive), and bacterial co-infections.
- Children with SMPP exhibited distinct inflammatory markers and required more aggressive treatments, including mechanical ventilation and non-macrolide antibiotics.
Conclusions:
- Severely ill children with SMPP demonstrate heightened inflammatory responses and a greater propensity for extrapulmonary complications.
- Treatment strategies for SMPP should consider hormonal therapy, anticoagulation, and targeted antibiotics for co-infections.
Objectives:
The increasing prevalence of severe Mycoplasma pneumoniae pneumonia (SMPP) poses a significant threat to the health of children. This study aimed to characterise and assess the outcomes in children with SMPP.
Methods:
We retrospectively analysed children hospitalised for M. pneumoniae pneumonia (MPP) between January and December 2022. Retrospectively, demographic, clinical, underlying diseases, laboratory and radiological findings, and treatment outcomes were collected and analysed. Disease severity was defined as severe or general according to the Guideline for diagnosis and treatment of community-acquired pneumonia in children (2019 version).
Results:
Over a 12-month observation period, 417 children with MPP were enrolled, 50.6% (211/417) of whom had SMPP, with the peak incidence observed in winter. Of the 211 children with SMPP, 210 were treated and discharged with improvement, while one child with congenital heart disease died of cardioembolic stroke. A significantly higher proportion of patients with SMPP had underlying diseases, extrapulmonary complications (myocardial and digestive system involvement), and bacterial co-infection. A total of 25 (12%) children with SMPP received mechanical ventilation. The median duration of mechanical ventilation was 3 days. All children were treated with macrolide antibiotic. A significantly higher proportion of patients with SMPP received antibiotic other than macrolides, methylprednisolone sodium succinate, intravenous immunoglobulin and anticoagulation, compared with patients with general MPP (GMPP). Children with SMPP had significantly higher levels of white blood cells, neutrophil percentage, C-reactive protein, procalcitonin, interferon-γ, interleukin (IL)-2, IL-5, IL-6, IL-8, IL-10 and significantly lower percentages of lymphocytes, monocytes, and natural killer cells, compared with GMPP group.
Conclusion:
Our findings suggest that severely ill children have more pronounced inflammatory reaction and extrapulmonary complications. For effective management of children with SMPP, hormonal, prophylactic, anticoagulant therapy, as well as the use of antibiotics other than macrolides for bacterial co-infections, could be incorporated into treatment regimens.
More Related Videos
07:43A Non-invasive and Technically Non-intensive Method for Induction and Phenotyping of Experimental Bacterial Pneumonia in Mice
Published on: September 28, 2016
12:21A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness
Published on: September 28, 2022
Related Concept Videos
01:30Pneumonia III: Complications and Assessment
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:29Pneumonia II: Pathophysiology
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include: